Acolbifene

Acolbifene (INN) (developmental code names EM-652, SCH-57068) is a nonsteroidal selective estrogen receptor modulator (SERM) which, as of 2015, is in phase III clinical trials for the treatment of breast cancer.[1][2]

Acolbifene
Clinical data
Other namesEM-652; SCH-57068
Drug classSelective estrogen receptor modulator
Identifiers
IUPAC name
  • (2S)-3-(4-hydroxyphenyl)-4-methyl-2-[4-(2-piperidin-1-ylethoxy)phenyl]-2H-chromen-7-ol
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC29H31NO4
Molar mass457.570 g·mol−1
3D model (JSmol)
SMILES
  • CC1=C([C@@H](OC2=C1C=CC(=C2)O)C3=CC=C(C=C3)OCCN4CCCCC4)C5=CC=C(C=C5)O
InChI
  • InChI=1S/C29H31NO4/c1-20-26-14-11-24(32)19-27(26)34-29(28(20)21-5-9-23(31)10-6-21)22-7-12-25(13-8-22)33-18-17-30-15-3-2-4-16-30/h5-14,19,29,31-32H,2-4,15-18H2,1H3/t29-/m0/s1
  • Key:DUYNJNWVGIWJRI-LJAQVGFWSA-N

See also

References
  1. Gauthier S, Cloutier J, Dory YL, Favre A, Mailhot J, Ouellet C, et al. (April 2005). "Synthesis and structure-activity relationships of analogs of EM-652 (acolbifene), a pure selective estrogen receptor modulator. Study of nitrogen substitution". Journal of Enzyme Inhibition and Medicinal Chemistry. 20 (2): 165–77. doi:10.1080/14756360500043448. PMID 15968821.
  2. "Acolbifene - Endoceutics". Adis Insight. Springer Nature Switzerland AG.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.